1. Retiform hemangioendothelioma treated with conservative therapy: report of a case and review of the literature
- Author
-
Yozo Ishiuji, Hidemi Nakagawa, and Yoshimasa Nobeyama
- Subjects
Male ,medicine.medical_specialty ,Skin Neoplasms ,Near critical ,Nose Neoplasms ,Lasers, Dye ,Antineoplastic Agents ,Imiquimod ,Dermatology ,Injections, Intralesional ,Administration, Cutaneous ,Triamcinolone Acetonide ,Nose neoplasm ,Hemangioendothelioma ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Glucocorticoids ,Survival rate ,Aged ,Retiform Hemangioendothelioma ,business.industry ,Standard treatment ,medicine.disease ,Surgery ,030220 oncology & carcinogenesis ,Aminoquinolines ,Vascular tumor ,business ,medicine.drug - Abstract
Background Retiform hemangioendothelioma (RH) is a locally aggressive vascular tumor. Wide surgical excision with tumor-free margins is the standard treatment strategy. However, surgical excision is not an option for lesions near critical anatomical structures, such as those on the face. We report the case of a patient with retiform hemangioendothelioma that responded to non-surgical treatments. Methods We describe the case of a 72-year-old male patient with a retiform hemangioendothelioma on the face that responded to a combination of pulsed dye laser, local corticosteroid injection, and application of imiquimod cream. In addition, we reviewed past case reports of patients with retiform hemangioendothelioma. Results Thirty-five cases that describe the management of RH, including the present case, have been reported. Review of the cases indicate a relatively low disease-free survival rate in cases that underwent surgical excision as the initial therapy for retiform hemangioendothelioma. Conclusion Surgical excision might not be the best therapeutic option. Local control with conservative therapy is an acceptable strategy for lesions in anatomical regions including the face.
- Published
- 2015